Notice of AGM (8979F)
June 21 2012 - 9:40AM
UK Regulatory
TIDMABH
RNS Number : 8979F
Angel Biotechnology Holdings Plc
21 June 2012
21 June 2012
Angel Biotechnology Holdings plc
("Angel" or "the Company")
Notice of Annual General Meeting
Angel Biotechnology Holdings plc, (AIM:ABH), the
biopharmaceutical contract manufacturer, announces that the
Company's Annual General Meeting will be held at 10am on 12th July
2012 at the offices of Grant Thornton UK LLP, 30 Finsbury Square,
London EC2A 1AG.
Copies of the Annual Report and Accounts for the period ended 31
March 2012 have been distributed to shareholders, together with the
Notice of Annual General Meeting and form of proxy.
An electronic copy of the Annual Report and Accounts 2012 is
available from the Company's website at www.angelbio.com
For further information:
Angel Biotechnology Holdings plc
Lorna Peers, Finance Director +44 (0) 131 445 6077
Stewart White, Acting CEO/Commercial Director
www.angelbio.com
Grant Thornton, Corporate Finance
Colin Aaronson / Melanie Frean +44 (0) 20 7383 5100
Hybridan LLP (Broker)
Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350
Media enquiries:
The Communications Portfolio Ltd
Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029
ariane.comstive@communications-portfolio.co.uk
Notes to Editors:
Angel Biotechnology Holdings plc is a full service contract
bio-manufacturing partner to biotechnology and pharmaceutical
companies worldwide. Angel specialises in advanced biologics
including biopharmaceutical proteins and cell therapies, such as
cellular vaccines and stem cells. At present, Angel's products are
principally used in pre-clinical studies and clinical trials with a
view to becoming the contract manufacturer of choice on a
continuing basis.
Drug development companies outsource their biopharmaceutical
manufacturing requirements to Angel to reduce their own capital
requirements and enable them to develop products more rapidly. In
addition, Angel provides complete regulatory services and
documentation to its customers while its manufacturing processes
adhere to the most stringent regulatory requirements. Products are
produced to current Good Manufacturing Practice (cGMP) standards as
required by the US Food and Drug Administration (FDA), and in
facilities that are certified to European standards by the
Medicines and Healthcare products Regulatory Agency (MHRA).
Its customers range from early-stage biotechnology companies
including ReNeuron plc and US-based Pathfinder Cell Therapy, to
established pharmaceutical companies such as Russian-based Materia
Medica Holdings.
Angel has three facilities: Pentlands Science Park near
Edinburgh where it employs 38 people, a site in Cramlington, near
Newcastle-upon-Tyne, which is expected to employ up to 10 people by
the end of 2012 and Angel Biomedical Ltd facility in Glasgow.
More information is available at www.angelbio.com .
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOABKDDQNBKDKAB
Angel Biotechnology (LSE:ABH)
Historical Stock Chart
From Apr 2024 to May 2024
Angel Biotechnology (LSE:ABH)
Historical Stock Chart
From May 2023 to May 2024
